Healthcare - Biotechnology - NASDAQ - US
$ 4.835
-0.103 %
$ 609 M
Market Cap
-3.81
P/E
CASH FLOW STATEMENT
-73.3 M
OPERATING CASH FLOW
-173 K
INVESTING CASH FLOW
4.51 M
FINANCING CASH FLOW
FREE CASH FLOW ANALYSIS
Free Cash Flow Analysis
Humacyte, Inc.
| Net Income | -111 M |
| Depreciation & Amortization | 7.72 M |
| Capital Expenditures | -2.28 M |
| Stock-Based Compensation | 6.83 M |
| Change in Working Capital | 6.57 M |
| Others | 18.1 M |
| Free Cash Flow | -75.6 M |
Cash Flow
Millions
| Dec-2023 | Dec-2022 | Dec-2021 | Dec-2020 | Dec-2019 | |
|---|---|---|---|---|---|
| OPERATING CASH FLOW | |||||
| Net Income | (110.8) | (12.0) | (26.5) | (66.5) | (85.4) |
| Depreciation & Amortization | 7.7 | 8.2 | 8.2 | 8.4 | 6.7 |
| Deferred Income Tax | 0 | (0.2) | (17.8) | 0.2 | (4.3) |
| Stock Based Compensation | 6.8 | 6.2 | 10.1 | 4.7 | 4.5 |
| Other Operating Activities | 16.4 | (74.4) | (54.7) | 0.1 | 2.0 |
| Change in Working Capital | 6.6 | 1.0 | (0.6) | (2.4) | 0.5 |
| Cash From Operations | (73.3) | (71.1) | (81.2) | (55.6) | (71.8) |
| INVESTING CASH FLOW | |||||
| Capital Expenditures | (2.3) | (1.0) | (0.2) | (0.3) | (8.1) |
| Other Items | 2.1 | 5.9 | (8.0) | 50 K | 0 |
| Cash From Investing Activities | (0.2) | 4.8 | (8.2) | (0.3) | (8.1) |
| FINANCING CASH FLOW | |||||
| Common Stock Repurchased | 0 | 0 | 0 | 0 | 0 |
| Total Debt Repaid | (34.1) | (2.0) | 27.9 | 1.8 | (1.3) |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 |
| Other Financing Activities | 38.6 | 0.5 | 239.1 | 0.3 | 1.2 |
| Cash From Financing Activities | 4.5 | (1.4) | 267.0 | 2.1 | 74 K |
| CHANGE IN CASH | |||||
| Net Change In Cash | (69.0) | (67.7) | 177.6 | (53.8) | (80.0) |
| FREE CASH FLOW | |||||
| Free Cash Flow | (75.6) | (72.2) | (81.4) | (55.9) | (79.9) |